Telomerase inhibition by peptide nucleic acids reverses `immortality' of transformed human cells
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Telomerase activity, the ability to add telomeric repeats to the ends of chromosomes, has been detected in most immortal cell lines including tumor cells, but is low or absent in most diploid, mortal cells such as those of somatic tissues. Peptide nucleic acids (PNAs), analogs of DNA or RNA which bind to complementary nucleic acids with very high affinity, were co-electroporated into immortal human cells along with a selectable plasmid. Introduction of PNAs inverse-complementary to telomerase RNA effectively inhibited telomerase activity in intact cells, shortened telomeres, reduced colony size, and arrested cell proliferation after a lag period of 5-30 cell generations, consistent with suppression of their 'immortality'. Electroporation of selection plasmid alone had no effect, while PNAs of altered sequence were markedly less effective in each assay. This constitutes the first demonstration of cell growth arrest through telomerase inhibition, upon treatment of intact cells with an exogenous compound which can be efficiently delivered in vivo. The phenotype of telomerase-inhibited transformed cells differs from senescence of normal diploid fibroblasts, but rather resembles the crisis state of incompletely transformed cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent work with PNAs introduced into cells by electroporation has shown decreased cell viability, supporting our findings (49).”
From Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death (1999) · cites this paper as [49]
Citations
Cites
Molecular Cloning: A Laboratory Manual
Sambrook, J., Fritsch, E., & Maniatis, T. (1989) · UCLA - Biblioteca de Ciencias de la Salud · Cited by 133,589
Molecular cloning: A laboratory manual
Deininger, P. (1990) · Analytical Biochemistry · doi:10.1016/0003-2697(90)90595-z · Cited by 84,682
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091 · cited 2×
“…repeats (TTAGGG in mammals) to the ends of chromosomes, is undetectable in most diploid, `mortal' cell types and strains (Counter et al., 1992; Kim et al., 1994), but has been observed in a majority of `immortal' cell lines ± aneuploid cells, whether tumor-derived or transformed in vitro,…”
BackgroundTelomeres shorten during ageing of human fibroblasts
Harley, C. B., Futcher, A. B., & Greider, C. W. (1990) · Nature · doi:10.1038/345458a0 · Cited by 5,750
Extension of Life-Span by Introduction of Telomerase into Normal Human Cells
Bodnar, A. G., Ouellette, M., Frolkis, M., Holt, S. E., Chiu, C.-P., Morin, G. B., Harley, C. B., Shay, J. W., Lichtsteiner, S., & Wright, W. E. (1998) · Science · doi:10.1126/science.279.5349.349 · Cited by 4,975
Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide
Nielsen, P. E., Egholm, M., Berg, R. H., & Buchardt, O. (1991) · Science · doi:10.1126/science.1962210 · Cited by 3,332 · cited 1×
“These molecules are resistant to biodegradation (Demidov et al., 1994) and anneal by Watson:Crick base-pairing to complementary RNA or DNA sequences with much higher a nity than the corresponding phosphodiester oligomers (Nielsen et al., 1991; Egholm et al., 1993).”
BackgroundA survey of telomerase activity in human cancer
Shay, J. W., & Bacchetti, S. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00062-2 · Cited by 2,794 · cited 1×
“…activity is observed in most neoplastic cells and tissues yet is low or absent in somatic tissues (Kim et al., 1994; Broccoli et al., 1995; Shay and Bacchetti, 1997), inhibitors of telomerase activity hold promise as anti-cancer agents which might attenuate the growth of tumors while…”
BackgroundThe RNA Component of Human Telomerase
Feng, J., Funk, W. D., Wang, S.-S., Weinrich, S. L., Avilion, A. A., Chiu, C.-P., Adams, R. R., Chang, E., Allsopp, R. C., Yu, J., et al. (1995) · Science · doi:10.1126/science.7544491 · Cited by 2,227 · cited 2×
“…appeared to enter crisis (see below), much as reported for HeLa cell clones stably transfected with a plasmid expressing antisense telomerase RNA (Feng et al., 1995), and for a human glioblastoma line stably transfected with the same anti-telomerase plasmid, although a subset of di erentiated…”
BackgroundTelomere Shortening and Tumor Formation by Mouse Cells Lacking Telomerase RNA
Blasco, M. A., Lee, H.-W., Hande, M. P., Samper, E., Lansdorp, P. M., DePinho, R. A., & Greider, C. W. (1997) · Cell · doi:10.1016/s0092-8674(01)80006-4 · Cited by 2,108
Counter, C. M., Avilion, A. A., LeFeuvre, C. E., Stewart, N. G., Greider, C. W., Harley, C. B., & Bacchetti, S. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05245.x · Cited by 2,096 · cited 1×
“…ability to add telomeric repeats (TTAGGG in mammals) to the ends of chromosomes, is undetectable in most diploid, `mortal' cell types and strains (Counter et al., 1992; Kim et al., 1994), but has been observed in a majority of `immortal' cell lines ± aneuploid cells, whether tumor-derived or…”
Background
Research works printed but not linked: 1
- Reid LH, Shesely EG, Kim HS and Smithies O. . 1991 Mol. Cell. Biol. 11: 2769–2777. · doi:10.1128/mcb.11.5.2769-2777.1991 · Paper page
Cited by
Cellular Senescence: Aging, Cancer, and Injury
Calcinotto, A., Kohli, J., Zagato, E., Pellegrini, L., Demaria, M., & Alimonti, A. (2019) · Physiological Reviews · doi:10.1152/physrev.00020.2018 · Cited by 1,270
“These approaches include: antisense oligonucleotides, targeting RNA component of telomerase (169, 185), chemical inhibitors of telomerase (286), oligonucleotides and nucleoside (144), small molecule pharmaceuticals that target human (h) TERT (24), gene therapy constructs, molecules that target telomere and telomerase-…”
BackgroundTelomeres, lifestyle, cancer, and aging
Shammas, M. A. (2011) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e32834121b1 · Cited by 681
Self-citationTelomere maintenance as a target for anticancer drug discovery
Neidle, S., & Parkinson, G. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd793 · Cited by 624
Herbert, B.-S., Pitts, A. E., Baker, S. I., Hamilton, S. E., Wright, W. E., Shay, J. W., & Corey, D. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.25.14276 · Cited by 539
Self-citationShay, J. W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.7.677 · Cited by 509
Cellular senescence, cancer and aging: the telomere connection
Campisi, J., Kim, S.-H., Lim, C.-S., & Rubio, M. (2001) · Experimental Gerontology · doi:10.1016/s0531-5565(01)00160-7 · Cited by 400
Cell senescence and telomere shortening induced by a new series of specific G-quadruplex DNA ligands
Riou, J. F., Guittat, L., Mailliet, P., Laoui, A., Renou, E., Petitgenet, O., Mégnin-Chanet, F., Hélène, C., & Mergny, J. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052698099 · Cited by 394
T cells and aging january 2002 update
Pawelec, G. (2002) · Frontiers in Bioscience · doi:10.2741/a831 · Cited by 369
Natural and pharmacological regulation of telomerase
Mergny, J.-L. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.4.839 · Cited by 352
Chemistry in human telomere biology: structure, function and targeting of telomere DNA/RNA
Xu, Y. (2011) · Chemical Society Reviews · doi:10.1039/c0cs00134a · Cited by 323
Mathon, N. F., & Lloyd, A. C. (2001) · Nature Reviews Cancer · doi:10.1038/35106045 · Cited by 308
Cellular delivery of peptide nucleic acid (PNA)
Koppelhus, U., & Nielsen, P. E. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00182-5 · Cited by 248
Nielsen, P. E. (2004) · Molecular Biotechnology · doi:10.1385/mb:26:3:233 · Cited by 199
White, L. K., Wright, W. E., & Shay, J. W. (2001) · Trends in Biotechnology · doi:10.1016/s0167-7799(00)01541-9 · Cited by 171
Dysfunctional homologous recombination mediates genomic instability and progression in myeloma
Shammas, M. A., Shmookler Reis, R. J., Koley, H., Batchu, R. B., Li, C., & Munshi, N. C. (2009) · Blood · doi:10.1182/blood-2007-05-089193 · Cited by 155
Self-citationDoyle, D. F., Braasch, D. A., Simmons, C. G., Janowski, B. A., & Corey, D. R. (2000) · Biochemistry · doi:10.1021/bi0020630 · Cited by 168
Self-citationNovel Nanosensors for Rapid Analysis of Telomerase Activity
Grimm, J., Perez, J. M., Josephson, L., & Weissleder, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2798 · Cited by 166
Telomerase activation, cellular immortalization and cancer
Hahn, W. C., & Meyerson, M. (2001) · Annals of Medicine · doi:10.3109/07853890109002067 · Cited by 142
Ludwig, A., Saretzki, G. C., Holm, P. S., Tiemann, F., Lorenz, M., Emrich, T., Harley, C. B., & von Zglinicki, T. (2001) · PubMed · doi:10.25405/ncl.34663959 · Cited by 138
Telomerase Inhibition and Cell Growth Arrest After Telomestatin Treatment in Multiple Myeloma
Shammas, M. A., Reis, R. J. S., Cheng, L., Koley, H., Hurley, L. H., Anderson, K. C., & Munshi, N. C. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0793-03 · Cited by 129
Self-citationTelomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo
Shammas, M. A., Koley, H., Bertheau, R. C., Neri, P., Fulciniti, M., Tassone, P., Blotta, S., Protopopov, A. I., Mitsiades, C. S., Batchu, R. B., et al. (2008) · Leukemia · doi:10.1038/leu.2008.81 · Cited by 122
Self-citationA novel inhibitor of human telomerase derived from 10H-indolo[3,2-b]quinoline
Caprio, V. E., Guyen, B., Opoku‐Boahen, Y., Mann, J., Gowan, S. M., Kèlland, L. R., Read, M. A., & Neidle, S. (2000) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00378-4 · Cited by 118
The cellular delivery of antisense oligonucleotides and ribozymes
Hughes, M. D., Hussain, M., Nawaz, Q., Sayyed, P. Z., & Akhtar, S. (2001) · Drug Discovery Today · doi:10.1016/s1359-6446(00)00326-3 · Cited by 111
Elayadi, A. N., Braasch, D. A., & Corey, D. R. (2002) · Biochemistry · doi:10.1021/bi025907j · Cited by 111
Self-citationTelomeres and telomerase as targets for anticancer drug development
Olaussen, K. A., Dubrana, K., Dômont, J., Spano, J., Sabatier, L., & Soria, J. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.08.007 · Cited by 112
Telomerase inhibition, oligonucleotides, and clinical trials
Corey, D. R. (2002) · Oncogene · doi:10.1038/sj.onc.1205063 · Cited by 107
Self-citationTelomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma.
Shammas, M. A., Reis, R. J. S., Akiyama, M., Koley, H., Chauhan, D., Hideshima, T., Goyal, R. K., Hurley, L. H., Anderson, K. C., & Munshi, N. C. (2003) · PubMed · Cited by 102
Self-citationShammas, M. A., Koley, H., Batchu, R. B., Bertheau, R. C., Protopopov, A., Munshi, N. C., & Goyal, R. K. (2005) · Molecular Cancer · doi:10.1186/1476-4598-4-24 · Cited by 92
Self-citationTelomerase Inhibitor Imetelstat (GRN163L) Limits the Lifespan of Human Pancreatic Cancer Cells
Burchett, K. M., Yan, Y., & Ouellette, M. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085155 · Cited by 83
Folini, M., Berg, K., Millo, E., Villa, R., Prasmickaite, L., Daidone, M. G., Benatti, U., & Zaffaroni, N. (2003) · PubMed · Cited by 88
Recognition of Chromosomal DNA by PNAs
Kaihatsu, K., Janowski, B. A., & Corey, D. R. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2003.09.014 · Cited by 88
Self-citationDragulescu‐Andrasi, A., Zhou, P., He, G., & Ly, D. H. (2004) · Chemical Communications · doi:10.1039/b412522c · Cited by 85
Telomerase as a therapeutic target for malignant gliomas
Komata, T., Kanzawa, T., Kondo, Y., & Kondo, S. (2002) · Oncogene · doi:10.1038/sj.onc.1205072 · Cited by 85
PNA oligomers as tools for specific modulation of gene expression
Pooga, M., Land, T., Bartfai, T., & Langel, Ü. (2001) · Biomolecular Engineering · doi:10.1016/s1389-0344(01)00075-2 · Cited by 83
Synthesis, Analysis, Purification, and Intracellular Delivery of Peptide Nucleic Acids
Braasch, D. A., & Corey, D. R. (2001) · Methods · doi:10.1006/meth.2000.1111 · Cited by 80
Self-citationTargeting telomerase for its advent in cancer therapeutics
Bajaj, S., Kumar, M. S., Peters, G. J., & Mayur, Y. (2020) · Medicinal Research Reviews · doi:10.1002/med.21674 · Cited by 79
Qi, L., Strong, M. A., Karim, B. O., Armanios, M. Y., Huso, D. L., & Greider, C. W. (2003) · PubMed · Cited by 79
Unwinding of nucleic acids by HCV NS3 helicase is sensitive to the structure of the duplex
Tackett, A. J., Wei, L., Cameron, C. E., & Raney, K. D. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.2.565 · Cited by 78
Shammas, M. A., Koley, H., Beer, D. G., Li, C., Goyal, R. K., & Munshi, N. C. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.026 · Cited by 75
Self-citationTelomeres and Telomerase: From Discovery to Clinical Trials
Corey, D. R. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.12.001 · Cited by 73
Self-citationChen, Z., Koeneman, K. S., & Corey, D. R. (2003) · PubMed · Cited by 72
Self-citationTelomeres and telomerase as targets for cancer therapy
Zimmermann, S., & Martens, U. M. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-6481-8 · Cited by 71
Zhou, P., Dragulescu‐Andrasi, A., Bhattacharya, B. K., O’Keefe, H. P., Vatta, P., Hyldig‐Nielsen, J. J., & Ly, D. H. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.06.052 · Cited by 67
Telomerase Inhibition in Cancer Therapeutics: Molecular-Based Approaches
Publisher, B. S. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706778521887 · Cited by 60
Elayadi, A. N., Demieville, A., Wancewicz, E. V., Monia, B. P., & Corey, D. R. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.8.1683 · Cited by 59
Self-citationRankin, A. M., Faller, D. V., & Spanjaard, R. A. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3282f5d4c2 · Cited by 58
Telomerase and cancer: time to move from a promising target to a clinical reality
Keith, W. N., Evans, T. R. J., & Glasspool, R. M. (2001) · The Journal of Pathology · doi:10.1002/path.1001 · Cited by 55
Shiraishi, T., & Nielsen, P. E. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh820 · Cited by 54
Pal, J., Bertheau, R. C., Buon, L., Qazi, A. M., Batchu, R. B., Bandyopadhyay, S., Ali‐Fehmi, R., Beer, D. G., Weaver, D. W., Reis, R. J. S., et al. (2011) · Oncogene · doi:10.1038/onc.2011.83 · Cited by 53
Self-citationTripathi, S., Chaubey, B., Ganguly, S., Harris, D., Casale, R. A., & Pandey, V. N. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki743 · Cited by 53
Tackett, A. J., Corey, D. R., & Raney, K. D. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.4.950 · Cited by 53
Self-citationTárkányi, I., & Aradi, J. (2007) · Biochimie · doi:10.1016/j.biochi.2007.09.002 · Cited by 52
Liver cell specific targeting of peptide nucleic acid oligomers
Zhang, X., Simmons, C. G., & Corey, D. R. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00198-6 · Cited by 52
Self-citationInduction of senescence‐associated growth inhibitors in the tumor‐suppressive function of retinoids
Roninson, I. B., & Dokmanovic, M. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10320 · Cited by 44
Telomere length and telomerase subunits as diagnostic and prognostic biomarkers in Barrett carcinoma
Gertler, R., Doll, D., Maak, M., Feith, M., & Rosenberg, R. (2008) · Cancer · doi:10.1002/cncr.23419 · Cited by 48
Pallini, R., Pierconti, F., Falchetti, M. L., D’Arcangelo, D., Fernandez, E., Maira, G., D’Ambrosio, E., & Larocca, L. M. (2001) · Journal of neurosurgery · doi:10.3171/jns.2001.94.6.0961 · Cited by 46
Rasmussen, F. W., Bendifallah, N., Zachar, V., Shiraishi, T., Fink, T., Ebbesen, P., Nielsen, P. E., & Koppelhus, U. (2006) · Oligonucleotides · doi:10.1089/oli.2006.16.43 · Cited by 45
Patel, S. D., Isalan, M., Gavory, G., Ladame, S., Choo, Y., & Balasubramanian, S. (2004) · Biochemistry · doi:10.1021/bi048892t · Cited by 45
Compton, S. A., Elmore, L. W., Haydu, K., Jackson‐Cook, C. K., & Holt, S. E. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.4.1452-1462.2006 · Cited by 45
Uziel, O., Beery, E., Dronichev, V., Samocha, K., Gryaznov, S. M., Weiss, L., Slavin, S., Kushnir, M., Nordenberg, Y., Rabinowitz, C., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009132 · Cited by 44
Senescence of Tumor Cells in Anticancer Therapy—Beneficial and Detrimental Effects
Piskorz, W. M., & Cechowska‐Pasko, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911082 · Cited by 44
Senescence; an endogenous anticancer mechanism
Vargas, J. E., Feltes, B. C., Poloni, J. D. F., Lenz, G., & Bonatto, D. (2012) · Frontiers in bioscience · doi:10.2741/4074 · Cited by 43
Telomerase inhibitors: targeting the vulnerable end of cancer?
Kèlland, L. R. (2000) · Anti-Cancer Drugs · doi:10.1097/00001813-200008000-00001 · Cited by 43
Telomeres and telomerase: Biological and clinical importance in dogs
Nasir, L. (2007) · The Veterinary Journal · doi:10.1016/j.tvjl.2007.01.024 · Cited by 42
Lu, R., Pal, J., Buon, L., Nanjappa, P., Shi, J., Fulciniti, M., Tai, Y., Guo, L., Yu, M., Gryaznov, S. M., et al. (2013) · Oncogene · doi:10.1038/onc.2013.103 · Cited by 42
Self-citationPeptide Nucleic Acids, Morpholinos and Related Antisense Biomolecules
Janson, C. G., & During, M. J. (2006) · Springer eBooks · doi:10.1007/0-387-32956-0 · Cited by 41
Shammas, M. A., Qazi, A. M., Batchu, R. B., Bertheau, R. C., Wong, J. Y. Y., Rao, M. Y., Prasad, M., Chanda, D., Ponnazhagan, S., Anderson, K. C., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0473 · Cited by 43
Self-citationPallini, R., Sorrentino, A., Pierconti, F., Maggiano, N., Faggi, R., Montano, N., Maira, G., Larocca, L. M., Levi, A., & Falchetti, M. L. (2005) · International Journal of Cancer · doi:10.1002/ijc.21613 · Cited by 40
Telomerase as a new target for the treatment of hormone-refractory prostate cancer
Biroccio, A., & Leonetti, C. (2004) · Endocrine Related Cancer · doi:10.1677/erc.1.00764 · Cited by 41
Targeting human telomerase for cancer therapeutics
Guittat, L., Alberti, P., Gómez, D., Cian, A. D., Pennarun, G., Lemarteleur, T., Belmokhtar, C., Boujemaa‐Paterski, R., Morjani, H., Trentesaux, C., et al. (2004) · Cytotechnology · doi:10.1007/s10616-004-5127-z · Cited by 39
Methods for assessing DNA hybridization of peptide nucleic acid–titanium dioxide nanoconjugates
Brown, E. M. B., Paunesku, T., Wu, A., Thurn, K. T., Haley, B., Clark, J., Priester, T., & Woloschak, G. E. (2008) · Analytical Biochemistry · doi:10.1016/j.ab.2008.08.020 · Cited by 38
Telomerase inhibitors for the treatment of cancer: the current perspective
Perry, P. J., Arnold, J. R. P., & Jenkins, T. C. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.12.2141 · Cited by 38
Long non-coding RNAs at work on telomeres: Functions and implications in cancer therapy
Gala, K., & Khattar, E. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.036 · Cited by 37
Natarajan, S., Chen, Z., Wancewicz, E. V., Monia, B. P., & Corey, D. R. (2004) · Oligonucleotides · doi:10.1089/oli.2004.14.263 · Cited by 37
Self-citationHao, Z., Luo, J., Cheng, J. Q., Li, L., Wang, Q.-Y., Li, L., He, D., & Yang, G. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.10.2016 · Cited by 36
Telomeres and Telomerase: A Modern Fountain of Youth?
de Magalhães, J. P., & Toussaint, O. (2004) · Rejuvenation Research · doi:10.1089/1549168041553044 · Cited by 37
Zhdanov, D. D., Pokrovsky, V. S., Pokrovskaya, M. V., Alexandrova, S. S., Eldarov, M. A., Grishin, D. V., Basharov, M. M., Gladilina, Y. A., Podobed, O. V., & Sokolov, N. N. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.08.078 · Cited by 31
Zhdanov, D. D., Pokrovsky, V. S., Pokrovskaya, M. V., Alexandrova, S. S., Eldarov, M. A., Grishin, D. V., Basharov, M. M., Gladilina, Y. A., Podobed, O. V., & Sokolov, N. N. (2017) · Cancer Medicine · doi:10.1002/cam4.1218 · Cited by 31
Peptide nucleic acids as antibacterial agents via the antisense principle
Nielsen, P. E. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.2.331 · Cited by 31
Ellipilli, S., Murthy, R. V., & Ganesh, K. N. (2016) · Chemical Communications · doi:10.1039/c5cc05342k · Cited by 29
Kumar, P., & Jain, D. R. (2015) · Tetrahedron · doi:10.1016/j.tet.2015.03.093 · Cited by 28
Inhibition of HIV-1 replication by anti-trans-activation responsive polyamide nucleotide analog
Kaushik, N., Basu, A., & Pandey, V. N. (2002) · Antiviral Research · doi:10.1016/s0166-3542(02)00024-4 · Cited by 27
Jackson, M. R., Bavelaar, B. M., Waghorn, P. A., Gill, M. R., El-Sagheer, A. H., Brown, T., Tarsounas, M., & Vallis, K. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3594 · Cited by 26
Shammas, M. A., Liu, X., Gavory, G., Raney, K. D., Balasubramanian, S., & Reis, R. J. S. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.01.003 · Cited by 26
Self-citationJørgensen, M. A., Agerholm-Larsen, B., Nielsen, P. E., & Gehl, J. (2011) · Oligonucleotides · doi:10.1089/oli.2010.0266 · Cited by 25
Furuta, M., Nozawa, K., Takemura, M., Izuta, S., Murate, T., Tsuchiya, M., Yoshida, K., Taka, N., Nimura, Y., & Yoshida, S. (2003) · International Journal of Cancer · doi:10.1002/ijc.11022 · Cited by 25
Enhancing Nucleic Acid Delivery By Photochemical Internalization
Bøe, S. L., & Hovig, E. J. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.78 · Cited by 24
Glasspool, R. M., Burns, S., Hoare, S. F., Svensson, C., & Keith, W. N. (2005) · Neoplasia · doi:10.1593/neo.04766 · Cited by 24
A kinetic model of telomere shortening in infants and adults
Sidorov, I. A., Gee, D., & Dimitrov, D. S. (2003) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2003.08.009 · Cited by 22
Telomerase: An Unusual Target for Cytotoxic Agents
Corey, D. R. (2000) · Chemical Research in Toxicology · doi:10.1021/tx0000872 · Cited by 20
Self-citationTiptoeing to chromosome tips: facts, promises and perils of today's human telomere biology
Fajkus, J., Šimíčková, M., & Maláska, J. (2002) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2001.1053 · Cited by 20
Possibility of inducing tumor cell senescence during therapy (Review)
Wang, G., Cheng, X., Zhang, J., Liao, Y., Jia, Y., & Qing, C. (2021) · Oncology Letters · doi:10.3892/ol.2021.12757 · Cited by 19
Cancer treatment by telomerase inhibitors: predictions by a kinetic model
Sidorov, I. A., Hirsch, K. S., Harley, C. B., & Dimitrov, D. S. (2003) · Mathematical Biosciences · doi:10.1016/s0025-5564(02)00132-3 · Cited by 18
Feng, R., Zhu, Z.-G., Li, J.-F., Liu, B., Yan, M., 尹浩然, & Lin, Y.-Z. (2002) · World Journal of Gastroenterology · doi:10.3748/wjg.v8.i3.436 · Cited by 18
Kaushik, N., & Pandey, V. N. (2002) · Virology · doi:10.1006/viro.2002.1630 · Cited by 17
Burchett, K. M., Etekpo, A., Batra, S. K., Yan, Y., & Ouellette, M. M. (2017) · Oncotarget · doi:10.18632/oncotarget.19410 · Cited by 16
Telomerase as a new target for pancreatic cancer treatment
Sato, N., Mizumoto, K., Nagai, E., & Tanaka, M. (2002) · Journal of Hepato-Biliary-Pancreatic Surgery · doi:10.1007/s005340200036 · Cited by 16
Telomerase inhibition and telomere erosion: a two-pronged strategy in cancer therapy
Odago, F., & Gerson, S. L. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00165-2 · Cited by 15
Kaushik, N. K., Talele, T. T., Monel, R., Palumbo, P., & Pandey, V. N. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.24.5099 · Cited by 15
Nielsen, P. E. (2003) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-004-4860-7 · Cited by 15
Metadata
- Authors
- Shammas, M. A., Simmons, C. G., Corey, D. R., & Shmookler Reis, R. J.
- Affiliations
- University of Arkansas for Medical Sciences (US)
- Howard Hughes Medical Institute (US)
- Venue
- Oncogene
- Published
- 1999-11-04
- Volume
- 18
- Issue
- 46
- Pages
- 6191-6200
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2093249575
- Cited by
- 135
- References
- 52
- Citations by year
- 2022: 2 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 2 · 2017: 3 · 2015: 2 · 2014: 1 · 2013: 4 · 2012: 1
- FWCI
- 8.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- telomerase inhibition, peptide nucleic acid, telomere shortening, cell immortalization, growth arrest, electroporation, telomerase RNA, senescence, cancer cells
- MeSH terms
- Amino Acid Metabolism, Inborn Errors, Ataxia Telangiectasia, Cell Division, Cell Line, Transformed, Cell Transformation, Neoplastic, Enzyme Induction, Enzyme Inhibitors, Humans, RNA, Messenger, Transfection, Cellular Senescence, Electroporation, Telomerase, Peptide Nucleic Acids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.